Niraparib In Recurrent IDH 1/2 Gliomas

Clinical trial NCT05406700 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05406700
Sponsor: Massachusetts General Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Low-grade Glioma IDH2 Gene Mutation Recurrent Glioma IDH1 Mutation Glioma, Malignant

Start date: 2023-05-18
Primary completion: 2026-07-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.